ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0680

Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0712

Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0753

Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0536

Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0738

Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0913

Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0928

Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Canadian Scleroderma Registry Database

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0632

Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0775

T and B Cell Responses to Common Tenascin-C Peptides in RA

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0838

T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0597

Telemedicine in Pediatric Rheumatology During COVID-19: The PR-COIN Experience

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0897

Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0601

The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0819

The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0773

The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease

RA – Etiology & Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].